NasdaqGS:GILDBiotechs
Does Gilead’s 2025 Rally Match Its Cash Flow Outlook and Oncology Pipeline Prospects
If you are wondering whether Gilead Sciences is still a smart buy after its big run up, or if the value has already been priced in, you are in the right place to unpack what the market might be missing.
Gilead has quietly pushed its share price to about $125.67, with returns of 3.6% over the last week, 0.3% over the past month, and a much stronger 36.8% year to date and 37.5% over the last year, building on a 65.1% three year and 168.8% five year climb.
Recent headlines around Gilead have...